Drug/Device Products High On Piper Analyst's List Of Y2K Trends
This article was originally published in The Gray Sheet
Executive Summary
The clinical efficacy of reducing restenosis by incorporating the anticancer agent paclitaxel with coronary stents is on the cusp of gaining greater clinical backing, Angiotech Pharmaceuticals indicated.
You may also be interested in...
Boston Scientific Sees Return To Double-Digit Growth In Second Half Of 2000
Resumption of Boston Scientific's historic 20%-plus annual sales growth rate will occur the second half of 2000, the company is assuring investors, as key holes in the firm's product pipeline are filled early in the year, including release of advanced coronary stent systems.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.